ICONIQ Capital LLC Has $794,000 Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• ICONIQ Capital LLC increased its holdings in Thermo Fisher Scientific by 137.4%, owning 1,595 shares valued at $794,000 as of the latest SEC filing.
• Several institutional investors have also recently acquired stakes in Thermo Fisher Scientific, contributing to the company having 89.23% of its stock owned by institutional entities.
• Thermo Fisher Scientific's recent quarterly earnings beat analysts' expectations with an EPS of $5.36 and revenue of $10.86 billion, reflecting a year-over-year revenue growth of 2.9%.

ICONIQ Capital LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 137.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,595 shares of the medical research company's stock after acquiring an additional 923 shares during the quarter. ICONIQ Capital LLC's holdings in Thermo Fisher Scientific were worth $794,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter worth about $31,000. IMA Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the 1st quarter worth about $35,000. Finally, Navigoe LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $37,000. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,896 shares of company stock valued at $8,593,838. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $500.2380 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The stock has a market capitalization of $188.90 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.74. The stock has a fifty day moving average of $443.02 and a 200-day moving average of $456.60.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.